PRCT
PROCEPT BioRobotics CorporationNASDAQHealthcare$25.12-0.95%ClosedMarket Cap: $1.42B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.62
P/S
4.35
EV/EBITDA
-13.81
DCF Value
$49.60
FCF Yield
-4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.7%
Operating Margin
-33.7%
Net Margin
-31.0%
ROE
-25.1%
ROA
-18.8%
ROIC
-23.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $76.4M | 60.6% | $-31.0M | $-29.8M | $-0.54 | — |
| FY 2025 | $308.1M | 63.7% | $-103.9M | $-95.6M | $-1.72 | — |
| Q3 2025 | $83.3M | 64.8% | $-23.2M | $-21.4M | $-0.38 | — |
| Q2 2025 | $79.2M | 65.4% | $-22.2M | $-19.6M | $-0.35 | — |
| Q1 2025 | $69.2M | 63.9% | $-27.4M | $-24.7M | $-0.45 | — |
| Q4 2024 | $68.2M | 64.0% | $-19.7M | $-18.9M | $-0.35 | — |
| FY 2024 | $224.5M | 61.1% | $-96.6M | $-91.4M | $-1.75 | — |
| Q3 2024 | $58.4M | 63.2% | $-22.4M | $-21.0M | $-0.40 | — |
| Q2 2024 | $53.4M | 59.0% | $-26.8M | $-25.6M | $-0.50 | — |
| Q1 2024 | $44.5M | 56.2% | $-27.6M | $-26.0M | $-0.51 | — |
| Q4 2023 | $43.6M | 48.8% | $-29.6M | $-27.5M | $-0.54 | — |
| FY 2023 | $136.2M | 52.2% | $-109.2M | $-105.9M | $-2.24 | — |